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Background: Carcinogenic risks of internal exposures to alpha-
emitters (except radon) are poorly understood. Since exposure to 
alpha particles—particularly through inhalation—occurs in a range 
of settings, understanding consequent risks is a public health priority. 
We aimed to quantify dose–response relationships between lung dose 
from alpha-emitters and lung cancer in nuclear workers.
Methods: We conducted a case–control study, nested within Bel-
gian, French, and UK cohorts of uranium and plutonium workers. 
Cases were workers who died from lung cancer; one to three controls 
were matched to each. Lung doses from alpha-emitters were assessed 
using bioassay data. We estimated excess odds ratio (OR) of lung 
cancer per gray (Gy) of lung dose.
Results: The study comprised 553 cases and 1,333 controls. Median 
positive total alpha lung dose was 2.42 mGy (mean: 8.13 mGy; 
maximum: 316 mGy); for plutonium the median was 1.27 mGy and 
for uranium 2.17 mGy. Excess OR/Gy (90% confidence interval)—
adjusted for external radiation, socioeconomic status, and smoking—
was 11 (2.6, 24) for total alpha dose, 50 (17, 106) for  plutonium, and 
5.3 (−1.9, 18) for uranium.
Conclusions: We found strong evidence for associations between 
low doses from alpha-emitters and lung cancer risk. The excess OR/
Gy was greater for plutonium than uranium, though confidence inter-
vals overlap. Risk estimates were similar to those estimated previ-
ously in plutonium workers, and in uranium miners exposed to radon 
and its progeny. Expressed as risk/equivalent dose in sieverts (Sv), 
our estimates are somewhat larger than but consistent with those for 
atomic bomb survivors. 
See video abstract at, http://links.lww.com/EDE/B232.
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Knowledge of long-term health effects of ionizing radiation is chiefly derived from studies of populations exposed to 
photons (X and γ rays), particularly the Japanese atomic bomb 
survivors1 and populations receiving external radiation doses 
through occupational, medical, and environmental exposures.2 
Less is known about long-term impacts of internal exposure 
to emitters of alpha particles. Because internal exposures to 
alpha-emitters occur in environmental, malicious, accidental, 
or occupational settings, understanding attendant long-term 
risks is a priority in radiation protection.
The nuclear industry encompasses a range of activi-
ties, for example, energy and isotope production, fuel manu-
facturing and reprocessing, production of nuclear weapons, 
and research. Monitoring of external photon exposures is 
relatively straightforward and many cohorts have complete 
records from the industry’s inception. Previous epidemio-
logic studies of nuclear workers have chiefly examined asso-
ciations between cancers and photon radiation exposure.3–5 
However, at some facilities—particularly those involved in 
the fuel cycle and weapons production—workers may receive 
internal doses from incorporation of radionuclides, in partic-
ular uranium and plutonium, by inhalation, ingestion, or con-
tamination of wounds. After inhalation/incorporation, doses 
to organs or tissues depend on the radionuclide/element, its 
physicochemical form, and intake route.6 Densely ionizing 
radiations such as alpha particles have a greater relative bio-
logic effectiveness than sparsely ionizing radiation such as 
X and γ rays for many cell toxicity endpoints. In radiologi-
cal protection—where the prevention of cancer is generally 
the limiting factor—the increased relative biologic effective-
ness of alpha particles is taken into account through the use 
of a radiation weighting factor (wR) of 20.
7 While sufficient 
evidence exists to classify internalized alpha-emitting radio-
nuclides as carcinogenic, and there is sufficient evidence to 
declare some radionuclides as human carcinogens (e.g., plu-
tonium and radon progeny), data on risks at low doses are 
lacking for plutonium, and direct evidence of carcinogenicity 
in humans is limited for uranium.8
Relatively large lung doses can result from inhaling 
uranium/plutonium, depending on lung solubilities of mate-
rials inhaled. Lung cancer risk from internal exposure to 
these radionuclides is therefore of interest. It is well estab-
lished that prolonged exposure to radon progeny increases 
lung cancer risk.9,10 Studies of cancer risks associated with 
plutonium have been conducted in highly-exposed individu-
als in the Mayak worker cohort (MWC)11 and less highly-
exposed workers at Sellafield,12 with uranium and plutonium 
in nuclear workers in the United States,13–16 and with thorium 
and radium in medical patients.17 Dose–response analyses 
have been conducted on individually-assigned plutonium 
doses in Mayak and Sellafield cohorts. The MWC currently 
provides most of the information in humans on plutonium 
dose–response for several outcomes18–22 though it is limited 
by scant bioassay data and no monitoring in a substantial 
portion of the population. Dosimetry in the few other stud-
ies in which individual-level lung doses from alpha-emitters 
have been reconstructed has largely been based on limited 
bioassay data, resulting in uncertain doses, particularly at 
low doses.
An increased risk of solid cancer in relation to exter-
nal radiation dose was found in the International Collab-
orative Study (ICS), a 15-country cohort study of nuclear 
workers23,24 and in the International Nuclear Workers Study 
(INWORKS), a continuation of the ICS restricted to United 
States, United Kingdom, and France.5 The ICS excluded 
workers with potential for internal exposure to alpha-emit-
ters as dose reconstruction was impracticable at the cohort 
level; smoking information was unavailable for the ICS and 
INWORKS. To complement these studies, and to address 
some limitations of MWC data, the current study was con-
ducted to improve lung cancer risks associated with internal 
exposure to alpha-emitters, particularly at low doses, and to 
account for potential confounders, for example, smoking. 
Specifically, this study aimed to quantify any dose–response 
relationship between cumulated lung dose from alpha-
emitters and lung cancer mortality among nuclear workers 
monitored for uranium and/or plutonium exposure in five 
European cohorts.
METHODS
Study Design
We conducted a case–control study of lung cancer mor-
tality, nested in a set of five cohorts identified in the much 
larger ICS, comprising workers from Belgium, France, and 
the United Kingdom (Table 1). This design reduced data col-
lection (internal monitoring and smoking) and individual dose 
reconstruction compared with a cohort study. Activities cov-
ered by these facilities include: nuclear research and devel-
opment, waste treatment, fuel production and reprocessing, 
construction and operation of experimental reactors, develop-
ment of fast breeder reactors, and nuclear weapons research 
and production.
Study Population
The study population included all workers monitored 
for internal exposure to plutonium and/or uranium through 
urinalysis on or after a date, t1, and employed for ≥1 year at a 
facility in a study cohort. t1 was defined as the date after which 
bioassay (urine) data could be used to produce accurate and 
unbiased dose assessments (Table 1).25 For uranium, t1 often 
corresponded to the start of operation of a facility; for pluto-
nium, early bioassay measurements were less reliable. Work-
ers with only pre-t1 data were excluded. Workers employed 
for <1 year were excluded, as they may not be comparable to 
longer-term workers in terms of cancer risk. Contract work-
ers were excluded as work histories and exposures could not 
be comprehensively reconstructed, and mortality could not be 
comprehensively followed up.
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We defined cases as all deaths within the study popula-
tions and mortality follow-up periods (Table 1) for which lung 
cancer was either the underlying cause of death or an associ-
ated cause where no other cancer was listed as an underlying 
cause. Controls were alive and at risk in the year of death of 
the case (“reference date”); one to three controls were matched 
to each case by age at reference date (within 5 years), sex and 
facility (for cohorts with more than one geographically dis-
tinct facility, the facility was used as the matching variable). 
Controls born closest to the date of birth of the case were pref-
erentially selected. Controls were eligible for reselection as a 
control for another case and for reselection as a case.
Dosimetry
We obtained individual annual external dose estimates 
based on personal dosimeters, compiled for each worker for 
the purposes of other epidemiologic studies.24,26 We esti-
mated individual lung doses from internally incorporated 
alpha-emitters—chiefly plutonium and uranium and some 
others (radium, actinium, thorium, curium, polonium, protac-
tinium, and americium)—for each subject annually from start 
of potential exposure up to and including the reference date 
of the relevant case. Doses were reconstructed from bioas-
say data (primarily urinalysis but also fecal analysis and in 
vivo monitoring if available) using a common methodology 
developed and tested by the study dosimetry subcommittee as 
detailed elsewhere.25 Start of potential exposure to plutonium 
and uranium was determined from work history records or set 
to just before the start of bioassay monitoring. Where study 
subjects had both pre- and post-t1 monitoring data during their 
work history, pre-t1 data were included and doses calculated 
for pre-t1 years. Long retention of plutonium and uranium in 
the body means that later more reliable bioassay data can pro-
vide information on earlier (pre-t1) exposures.
For workers employed at more than one facility or sev-
eral times at the same facility, we reconstructed dosimetric 
and occupational histories, with final dose assessments con-
ducted at the facility of last employment.
Calculated doses depended on assumptions regarding 
the physicochemical properties of the radioactive materials 
to which a worker was exposed, lung absorption character-
istics, and intake (exposure) regimes (acute or chronic). We 
generated four indices of internal dose: total alpha dose (all 
radionuclides); alpha dose from plutonium; alpha dose from 
uranium; and dose from other alpha-emitters.
We estimated doses using the Human Respiratory Tract 
Model (HRTM),27 in which the lung is partitioned into three 
regions: bronchial (BB), bronchiolar (bb), and alveolar intersti-
tial (AI). Doses were estimated to each region, and to the whole 
lung, because doses to these regions from radionuclide-bearing 
aerosols vary and the radiosensitivities of cells in these regions 
TABLE 1. Study Populations, Study Periods, and t1 Date
Cohort Study Population
Recruitment 
Period
Mortality  
Follow-up Period
Internal Exposure  
Monitoring Period
Start End Start End Pu t1
a U t1
b
Belgium Employees of SCK·CEN, Belgonucleaire, and 
Belgoprocess
1969 2002 1969c 2002 1960 1960
France Employees of CEA and Areva NC (former COGEMA), 
who never worked as miners, were employed at 
facilities grouped as North (La Hague, Brennilis), 
Paris (Saclay, Fontenay-aux-Roses), and South 
(Pierrelatte, Marcoule, Grenoble, Cadarache), 
were monitored for plutonium or uranium through 
urinalysis, and were monitored for external radiation 
only from 1967
1950 1994 1968d 2003 1967 1967
UKAEA All UKAEA workers at Harwell, Winfrith, and Dounreay 1946 2002 1946 2002 1970 1946 (Harwell)
1955 (Dounreay)
1957 (Winfrith)
AWE All AWE workers employed at Aldermaston 1950 1982 1950 2002 1963 1960
BNFL All BNFL and UKAEA workers at BNFL Sellafield 
and Springfields monitored for plutonium (post-1970 
exposure) and/or uranium exposure through urine 
analyses
1949 2002 1949 2002 1971 (exposure at 
Sellafield only)
1948
aThe date after which urinalysis data could be used to produce accurate and unbiased dose assessments for plutonium.
bThe date after which urinalysis data could be used to produce accurate and unbiased dose assessments for uranium.
cIndividual causes of death not available before this date.
dSCK·CEN.
AWE indicates Atomic Weapons Establishment; BNFL, British Nuclear Fuels Limited; CEA, Commissariat à l’énergie atomique; COGEMA, Compagnie générale des matières 
nucélaires; SCK·CEN: Studiecentrum voor Kernenergie·Centre d’Étude de l’énergie Nucléaire; UKAEA: United Kingdom Atomic Energy Authority.
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are assumed to differ. We estimated doses for four cell types: 
basal (BBbas) and secretory (BBsec) cells (BB region), Clara 
cells (bb region), and endothelial cells (AI region). We summed 
regional doses using weights of 1/3 for AI and bb regions and 
1/6 for BBsec and BBbas subregions.
27 This weighted lung dose 
has been used in epidemiologic studies of radon and its prog-
eny28 and is extensively used in radiation protection.9 Studies 
of MWC have used a different approach, wherein dose is cal-
culated as total energy deposited in the lung divided by lung 
tissue mass. We estimated mass-averaged doses for sensitivity 
analysis (weights: BB = 0.0006; bb = 0.0017; AI = 0.9977).
Potential Confounding
Information was available on the matching variables—
age, sex, and facility—and socioeconomic status (SES). 
Facility is important in controlling for potential occupational 
coexposures and geographically determined factors (e.g., nat-
ural background radiation). SES is a surrogate for lifestyle fac-
tors associated with cancer including smoking and diet. SES 
was assigned to each subject based on job title—either at time 
of hiring (France), last job (UKAEA, AWE), or job of lon-
gest duration (other cohorts). For AWE, Belgium, France, and 
UKAEA, we assigned SES according to a regrouping of the 
British Registrar General’s classification, from 1 (unskilled) 
to 4 (intermediate and professional).29 For BNFL, detailed 
classification was not possible so workers were assigned cate-
gories 5 and 6, indicating “industrial” (paid weekly) and “non-
industrial” (paid monthly) work, respectively (eTable 1; http://
links.lww.com/EDE/B205); “nonindustrial” included mana-
gerial, scientific, and clerical staff; “industrial” comprised the 
remainder. For sensitivity analysis, we recoded SES: catego-
ries 1, 2, and 5 were combined (lower SES), and categories 3, 
4, and 6 were combined (higher SES).
Smoking is the main risk factor for lung cancer and 
an important potential confounder in this study. The record-
based nature of this study precluded collection of compre-
hensive information on lifetime smoking status. Smoking 
information was extracted from occupational medical 
records from routine medical examinations. For Belgium 
and AWE, smoking information was well documented for 
entry examinations but not in subsequent ones. For UKAEA 
and BNFL, information was available for ~40% of workers 
but completeness of records was heterogeneous. In France, 
smoking information was not recorded in early time periods. 
From the mid-1970s, such information was collected more 
systematically in all facilities. Given the heterogeneous 
data available for each worker’s employment history, and 
no definitive retrospectively-collected data regarding life-
time smoking habits, “never smoker” was assigned if any 
data after the age of 40 indicated the worker never having 
smoked. “Ever smoker” was assigned when any record of 
smoking appeared in medical records. Where neither condi-
tion was met (or information was unavailable) “unknown” 
status was assigned.
Statistical Analysis
The aim of the study was to derive estimates of the 
excess relative risk (in terms of the excess odds ratio) of lung 
cancer per gray (Gy) of absorbed dose to the lung from alpha-
emitters as a group and for plutonium and uranium separately. 
All information was truncated at the reference date. We fitted 
conditional logistic regression models based on matched sets 
using EPICURE software.30 The excess OR/Gy was estimated 
using a mixture model comprising a linear function of radia-
tion dose (both internal and external) and a loglinear function 
of covariates, as is typical in radiation epidemiology, defined:
EOR = +α ββs i x ze zx( ) ( ),1
where x is a vector of covariates, βx are the covariate param-
eters to be estimated, z  is a vector of cumulated doses (both 
internal and external) minus lag, βz  is a vector of dose–
response slopes, that is, the excess OR/Gy to be estimated, 
and α s i( ) is a set of stratum parameters indicating numbers of 
cases and controls in each matched set. In common with most 
modern radiation epidemiology studies, we investigated the 
magnitude of increased cancer risk associated with radiation 
exposure, and therefore followed the convention of reporting 
90% confidence intervals (CIs) and one-sided P values. Pro-
file likelihood-based CIs were estimated.
Main analyses were adjusted systematically for exter-
nal dose, SES, and smoking through inclusion in the model—
external dose in the linear subterm, all other covariates in 
the loglinear subterm—and for age, sex, and facility through 
matching. Age at start of employment and duration of employ-
ment were investigated as potential confounders of associa-
tions between lung cancer and alpha dose, by including them 
in the model and evaluating whether estimates of radiation-
induced risk changed by ≥10%. We investigated effect modi-
fication of the association of lung cancer with alpha dose by 
attained age, age at start of employment, and duration of expo-
sure, and by sex, cohort, smoking, and SES. For each model 
an interaction term was introduced as an exponent of alpha 
dose. Heterogeneity of risk was evaluated using a likelihood 
ratio test between models including and excluding the interac-
tion. Departures from linear dose–response for alpha doses—
including quadratic and logarithmic transformations in the 
linear term (logarithm of dose + 1 to prevent exclusion of 
zero-dose subjects)—were investigated. We assessed fit using 
likelihood ratio test (dose + dose2) and Bayesian information 
criterion (log(dose + 1)).
We lagged cumulated doses—both internal and exter-
nal—by 10 years as is typical in studies of nuclear work-
ers and lung cancer.23 Doses lagged by 5 and 15 years were 
estimated for sensitivity analysis. Other sensitivity analyses 
included: no adjustment for SES or smoking, restricting to 
men, and exploring heterogeneity among cohorts by running 
models that omitted cohorts one by one. The highly skewed 
dose data (a large proportion of workers had zero or near-zero 
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doses) precluded extensive categorical analysis: four catego-
ries were defined based on inspection of histograms of dose.
RESULTS
In total, 553 cases of lung cancer and 1,333 controls were 
included (Table 2); nine controls subsequently became cases. A 
total of 67% of subjects were ≥65 years old at reference date. 
Most began employment before 1965, ~35% before 1955. Mean 
date of death was 1989 (median: 1988, SD: 10.5). BNFL contrib-
uted the largest number of subjects (339 cases; 1,010 controls).
Distributions of internal alpha doses and photon doses 
were highly positively skewed (eTable 2; http://links.lww.
com/EDE/B205). Median positive alpha dose to the lung from 
all radionuclides was 2.43 mGy (mean: 8.13 mGy; maximum: 
316 mGy; interquartile range width [IQRw]: 7.76 mGy). 
Median positive alpha doses were 1.27 mGy for plutonium 
(mean: 5.09 mGy; maximum: 110 mGy; IQRw: 4.27 mGy) 
and 2.17 mGy for uranium (mean: 6.45 mGy; maximum: 302 
mGy; IQRw: 5.93 mGy). The number of subjects with positive 
doses was 711 for plutonium, 1,409 for uranium, and 56 for 
other alpha-emitters.
Median total alpha doses were highest to BBsec and 
lowest to BBbas (eFigure 1; http://links.lww.com/EDE/B205). 
Regional doses were highly correlated (Spearman’s rho ≥0.93 
for uranium and plutonium). Ranges and medians of average 
lung doses generated using the alternative weighting scheme 
were similar (eFigure 2; http://links.lww.com/EDE/B205).
We found a dose–response relationship for total alpha 
dose: the excess OR/Gy adjusted for external dose, smok-
ing, and SES was 11 (90% CI: 2.6, 24; Table 3). The excess 
OR/Gy for plutonium and uranium adjusted for external 
dose, smoking, and SES were 50 (90% CI: 17, 106) and 5.3 
(90% CI: −1.9, 18), respectively. Although CIs were wide and 
overlapped, we demonstrated a difference between deviances 
of models (adjusted for SES, smoking status, and photon 
dose) of combined uranium and plutonium doses and of the 
two doses separately (likelihood ratio test P value = 0.03). 
Repeating the analysis for plutonium omitting the seven sub-
jects with plutonium dose ≥50 mGy gave an excess OR/Gy of 
35 (90% CI: 3.5, 88), which was lower but statistically com-
patible with the main plutonium result. No dose–response 
relationship was found for external radiation dose: excess 
OR/Gy adjusted for smoking and SES was −0.38 (90% CI: 
−0.58; 0.14; Table 3).
Most subjects smoked during their lifetime (84% of 
cases; 62% of controls). Few workers never smoked (1% of 
cases; 4% of controls). Smoking status was unknown for 17% 
of cases and 38% of controls. Odds ratios of lung cancer due 
to smoking were 9.2 (90% CI: 4, 21) for ever smokers and 
2.5 (90% CI: 1.1, 5.9) for those of unknown smoking status 
(eTable 3; http://links.lww.com/EDE/B205).
Removing SES or smoking from the model (eTable 
4; http://links.lww.com/EDE/B205) led to ≥10% change in 
excess OR/Gy for total alpha, uranium, and plutonium doses 
(with the exception of SES for plutonium) suggesting that 
both variables confound associations between lung cancer and 
alpha dose. Reclassification of SES into two groups resulted 
in little change to the risk estimates (eTable 5; http://links.
lww.com/EDE/B205).
We found no evidence for effect modification of 
total alpha dose by smoking (P value: 0.35), attained age 
TABLE 2. Distribution of Key Characteristics of Subjects
 
Cases
(n = 553)
Controls 
(n = 1,333)
Cohort
  Belgium—SCK·CEN, Belgoprocess, and 
Belgonucleaire
9 19
  France–CEA-COGEMA 17 36
  UKAEA 97 108
  UK—AWE 91 160
  UK—BNFL 339 1,010
Sex
  Men 544 1,319
  Women 9 14
Age at death of case (reference date)
  <55 54 135
  55–64 132 318
  65–74 242 570
  75+ 125 310
Year of first exposure to alpha-emitters  
(dose > 0 mGy)a
  <1955 167 496
  1955–1964 179 417
  1965–1974 99 167
  1975+ 107 250
Year of death of case (reference date)
  <1975 75 202
  1975–1985 139 322
  1985–1995 191 451
  >1995 148 358
Socioeconomic status
  All centers except BNFL
   1 (unskilled) 32 82
   2 (partly skilled) 12 33
   3 (skilled manual and nonmanual) 60 78
   4 (intermediate and professional) 110 130
  BNFL
   5 (industrial) 301 805
   6 (nonindustrial) 38 205
Smoking
  Never 6 48
  Ever 457 802
  Unknown 90 483
an = 1,882: three controls and one case have no dose recorded for study period.
AWE indicates Atomic Weapons Establishment; BNFL, British Nuclear Fuels 
Limited; CEA, Commissariat à l’énergie atomique; COGEMA, Compagnie générale 
des matières nucélaires; SCK·CEN, Studiecentrum voor Kernenergie·Centre d’Étude de 
l’énergie Nucléaire; UKAEA, United Kingdom Atomic Energy Authority.
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(P value: >0.50), age at start of employment (P value: >0.50), 
SES (P value: 0.08), cohort (maximum likelihood estimate 
for some parameters could not be calculated), or duration of 
employment (P: >0.50). Similarly, no effect modification by 
any covariate was identified for dose from plutonium or ura-
nium individually.
We detected no evidence of departures from linearity in 
the associations for total alpha, plutonium, or uranium. Like-
lihood ratio tests indicated that the fits of models of dose + 
dose2 were no improvement over linear models for total alpha 
(P: 0.12), plutonium (P: 0.07), and uranium (P: 0.14). Infor-
mation criteria also indicated that fits of models of log(dose + 
1) were no improvement over linear models of dose for total 
alpha (Bayesian information criterion 1,203.72 vs. 1,203.57 
for linear dose model), plutonium (Bayesian information cri-
terion 1,199.54 vs. 1,199.44), and uranium (Bayesian infor-
mation criterion 1,208.31 vs. 1,208.25).
Results of categorical analyses are plotted in the Figure. 
For plutonium, the excess OR for the highest category was 
very high, but based on small numbers of subjects (Table 4), 
with very wide CIs that just include the estimate from the 
model using the continuous form of the exposure variable. 
Sensitivity analyses were carried out with reference categories 
of zero dose: patterns of risk estimates for all internal dose 
variables were similar to those observed in the main analyses 
(eTable 6; http://links.lww.com/EDE/B205).
Sensitivity analyses of 5- and 15-year lags produced 
excess OR/Gy similar to those for 10-year lags (eTable 7; 
http://links.lww.com/EDE/B205). Restricting to males (n = 
1,863) gave an excess OR/Gy for total alpha dose of 11 (90% 
CI: 2.6, 24), essentially identical the main analysis result. 
Numbers were too low to restrict to females.
Estimates of excess OR/Gy for individual lung regions 
were heterogeneous, particularly for total alpha dose (eTable 
8; http://links.lww.com/EDE/B205). Generally, however, 
CIs on the dose–response estimates were wide and over-
lapping. Deviances of models of excess OR/Gy of regional 
alpha doses were consistently lowest for the AI region for all 
nuclides. Although median average lung doses were simi-
lar to International Commission on Radiological Protection 
(ICRP)- weighted lung doses (analyses restricted to UK 
cohorts as doses to individual lung regions were not avail-
able elsewhere), the risk estimates for the two sets of doses 
differed although CIs were wide and overlapped (eTable 9; 
http://links.lww.com/EDE/B205). Differences between the 
ratios of the risk estimates for plutonium versus uranium 
for individual regions of the lung were small (eTable 8; 
http://links.lww.com/EDE/B205). Risks for plutonium were 
greater than those for uranium by factors of ~7 (BBbas) to 
~15 (bb). Risk estimates for plutonium using average lung 
dose were ~80% of those estimated using the ICRP weighted 
dose, compared with ~200% for uranium. Risks for total 
alpha dose were higher for average lung dose than ICRP 
weighted dose. For all dose indices, however, CIs were wide 
and the results obtained using either weighting system are 
similar.
DISCUSSION
This multinational case–control study, combining data 
from those European nuclear industry cohorts with substantial 
numbers of workers exposed to uranium and/or plutonium, is the 
first large-scale study in which lung doses from both nuclides 
have been estimated using common dosimetric models.
We found strong evidence that internal exposure to 
alpha-emitters in the lung increases lung cancer risk even 
at the low doses experienced by nuclear industry work-
ers. A linear model proved adequate to describe the shape 
of dose–response for total alpha, plutonium, and uranium 
doses. External radiation dose did not confound these associa-
tions. Smoking and SES confounded these associations; the 
degree to which confounding by smoking was controlled was 
TABLE 3. EOR per Gy for Lung Cancer—Matched on Sex, 
Age, and Cohort, Lag of 10 Years
 EOR/Gy (90% CIa)
Unadjusted models
  Total alpha dose 13 (4.3, 27)
  Plutonium alpha dose 44 (14, 92)
  Uranium alpha dose 8 (−0.42, 21)
  External dose −0.36 (<0b, )0.09
Models adjusted only for external dose
  Total alpha dose 14 (4.9, 27)
  External dose −0.41 (<0b, −0.00)
  Plutonium alpha dose 43 (15, 90)
  External dose −0.39 (−0.57, 0.03)
  Uranium alpha dose 8.7 (−0.01, 22)
  External dose −0.38 (−0.58, 0.05)
Fully adjusted modelsc
  Total alpha dose 11 (2.6, 24)
  External dose −0.43 (−0.61, 0.04)
  Plutonium alpha dose 50 (17, 106)
  External dose −0.4 (−0.58, 0.06)
  Uranium alpha dose 5.3 (−1.9, 18)
  External dose −0.39 (−0.59, 0.1)
  Plutonium alpha dose 49 (16, 106)
  Uranium alpha dose 4.2 (−2.5, 17)
  External dose −0.44 (−0.6, 0.04)
  Plutonium alpha dose 49 (16, 106)
  Uranium alpha dose 4.2 (−2.5, 17)
  Other radionuclides alpha dose 3.7 (−3, 42)
  External dose −0.44 (−0.6, 0.04)
  External dose −0.38 (−0.58, 0.14)
All analyses for 553 cases and 1333 controls; alpha doses and external doses 
included in linear subterm of all models.
aCI based on likelihood profile.
b<0: lower CI is on boundary of parameter space (1/max dose).
cAdjusted for smoking and socioeconomic status (loglinear subterm).
EOR, excess odds ratio.
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potentially limited by a low proportion of lifetime nonsmokers 
and relatively high proportion of subjects for which definitive 
smoking data were not available (eTable 3; http://links.lww.
com/EDE/B205).
In radionuclide-specific analyses, excess OR/Gy were 
higher for plutonium than for uranium. Although CIs associ-
ated with estimates for plutonium and uranium were wide and 
overlapped, the difference in the estimates was statistically 
significant. Given uncertainties in doses (not presented here), 
we cannot draw clear conclusions regarding this difference. 
Also, since the dosimetry protocol was agreed, modifications 
to the HRTM have been recommended32 and proposals submit-
ted for updated lung solubility parameters for plutonium and 
uranium compounds which might differentially affect doses. 
Although impacts of these modifications were considered in an 
uncertainty analysis (not presented here), it would be useful to 
estimate risk in this population using dosimetry including the 
updated model, and to explore the influence on risk estimates 
FIGURE. Excess odds ratio (90% confidence intervals) for categorical analysis of alpha dose, adjusted for smoking, socioeconomic 
status, and external dose with trend from continuous analysis of alpha dose (90% confidence interval).
TABLE 4. Distribution of Subjects by Dose Category and Results of Categorical Analysis, Adjusted for External Dose, 
Socioeconomic Status and Smoking, 10-year Lag
Dose Dose Levels (mGy) Cases Controls Excess Odds Ratio (90% CIa)
Total alpha dose [0, 10]b 439 1,081 0
(10, 25] 61 178 −0.23 (−0.43, 0.02)
(25, 50] 31 58 0.38 (−0.09, 1.1)
(50, ∞] 22 16 1.3 (0.25, 3.5)
Plutonium alpha dose [0, 10]b 507 1,271 0
(10, 25] 30 53 0.07 (−0.33, 0.73)
(25, 50] 10 8 3.2 (0.56, 11)
(50, ∞] 6 1 25 (3.2, 341)
Uranium alpha dose [0, 10]b 491 1,161 0
(10, 25] 33 126 −0.31 (−0.52, −0.03)
(25, 50] 19 39 0.29 (−0.21, 1.1)
(50, ∞] 10 7 0.60 (−0.34, 3)
Other radionuclides alpha dose [0, 10]b 545 1,323 0
(10, 25] 4 1 11 (1, 143)
(25, 50] 1 5 −0.49 (−0.95, 1.6)
(50, ∞] 3 4 0.45 (−0.64, 4.8)
External dosec [0, 100]b 448 1,059 0
(100, 250] 64 137 −0.06 (−0.32, 0.28)
(250, 500] 25 82 −0.43 (−0.66, −0.06)
(500, ∞] 16 55 −0.37 (−0.69, 0.03)
a90% CI based on likelihood profile.
bReference category.
cAdjusted only for socioeconomic status and smoking.
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of individual-level dosimetric information, such as numbers 
of bioassays, bioassay data below detection limits, solubility 
assumptions, and calculated intakes.
Our estimate of excess OR/Gy for total alpha dose is 
higher than, but compatible with, that of previous studies 
of prolonged exposure to alpha-emitters (Table 5), namely 
for radon exposure in the French uranium miners cohort 
(FUMC)28 and for plutonium in the MWC,11 where doses 
were higher than in our study. The risk estimates in the present 
study for plutonium dose—and specifically for male smok-
ers, for comparison with the MWC—are higher than those 
reported for the MWC.11,22,33 The reasons for this are unclear, 
although differences between the current study cohorts and 
MWC in terms of monitoring regimes, dosimetry and asso-
ciated uncertainties, distributions of dose, and potential con-
founding by occupational carcinogens may play a role. The 
dosimetry used in our study was based on more extensive 
individual biomonitoring data than MWC which led to more 
accurate (though still uncertain) dose estimates, particularly at 
low doses.25 Our findings are particularly important as other 
studies of populations internally-exposed to plutonium at 
doses lower than those in the MWC12,14,34,35 have not provided 
clear evidence of increased risk of lung cancer with increasing 
plutonium dose.11 Using a wR of 20 to express risk in terms of 
equivalent dose to the lung in Sv, our estimates are compatible 
with those of the atomic bomb survivors.1 We were unable 
to compare our results with many underground miner studies 
that present risk in terms of working level months. The FUMC 
study, however, reported ERR/Gy for lung cancer mortality 
and lung alpha doses of 4.5 (95% CI: 1.3, 11),28 which is com-
patible with our results for total alpha dose.
We found no clear evidence of effect modification by age 
at start of employment, or duration of employment, although 
the generally low doses meant we had little statistical power to 
test for this. The similarity of results for different lags reflects 
much of the exposure having occurred many years before ref-
erence dates (mainly before the 1960s).
Although we found no evidence of effect modification 
by smoking, an excess OR/Gy of 7.2 (90% CI: −0.3, 21) was 
estimated for total alpha dose (adjusted for SES) in an analysis 
restricted to smokers, which indirectly suggests a similar pat-
tern to that observed in the MWC, cohorts of uranium miners, 
residents exposed to environmental radon, and atomic bomb 
survivors,36 where the modifying effect of smoking on radia-
tion is submultiplicative.
We found no clear evidence of effect modification by 
cohort. We could not estimate excess OR/Gy for some cohorts 
individually due to small numbers: models for Belgium, 
France, and UKAEA failed to converge; effect measures for 
AWE and BNFL individually were imprecise, prohibiting 
interpretation (results for BNFL in eTable 10; http://links.lww.
com/EDE/B205). However, heterogeneities in risk estimates 
observed when omitting cohorts one-by-one (eTable 11; http://
links.lww.com/EDE/B205) suggest differences in risks among 
them. Omitting Belgium, France, or UKAEA had a limited 
impact on excess OR/Gy for total alpha, plutonium, or ura-
nium. Omitting both Belgium and France (see ICRP weighted 
lung dose estimates in eTable 9; http://links.lww.com/EDE/
TABLE 5. Comparison of Current Study Results with Other Studies
 Study
Radionuclide/ 
Radiation n Cases
Mean Dose  
of Subjects
Excess Relative Risk/Gy or 
Sva (Confidence Interval)
Lung absorbed doses Current study U + Pu + external 553 7.42 mGy 11 (2.6b, 24b)
  Malesc U + Pu + external 544 7.47 mGy 11 (2.6b, 24b)
  Smokersd U + Pu + external 457 8.05 mGy 7.2 (−0.27b, 21b)
  Malesc Pu + external 544 1.92 mGy 48 (16b, 102b)
  Smokersd Pu + external 457 1.82 mGy 30 (0.03b, 93b)
  Male smokersd Pu + external 451 1.81 mGy 29 (−0.39b, 91b)
Mayak11
  Males Pu 446 93 mGy 7.4 (5e, 11e)
  Females Pu 40 165 mGy 24 (11e, 56e)
French Uranium miners28 U + external + Rn 66 78 mGy 4.5 (1.3b, 11b)
Lung equivalent doses 
(Relative biologic 
effectiveness = 20)
Current study U + Pu 553 148 mSv 0.55 (0.13b, 1.2b)
Atomic bomb survivorsf External 219 600 mGy 0.30 (0.08b, 0.56b)
Mayak Pu 486 1980 mSv 0.35 (0.24e, 0.5e)
French uranium miners U + Rn 66 1560 mSv 0.22 (0.06e, 0.54e)
aExcess odds ratio for current case–control study.
b90% confidence interval.
cAdjusted for socioeconomic status and smoking.
dAdjusted for socioeconomic status.
e95% confidence interval.
fRestricted to males of working age (20–65)—authors’ analysis of the radiation effects research foundation (RERF) life span study (LSS) Report 14 data.38
Pu indicates plutonium; Rn, radon; U, uranium.
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B205) also had limited impact. Omitting AWE decreased 
excess OR/Gy for total alpha, plutonium, and uranium doses. 
It appears that AWE subjects with relatively higher doses may 
be influential in the analyses. Omitting BNFL had little impact 
on excess OR/Gy for plutonium dose, but increased excess 
OR/Gy for uranium dose (and subsequently for total alpha 
dose). Some of the heterogeneity may result from subtle differ-
ences in matching: although controls were matched on facility 
in all cohorts, in BNFL this resulted in a tendency to match on 
radionuclide (Sellafield workers were typically exposed only 
to plutonium, workers at Springfields only to uranium). This 
would potentially reduce contrasts in dose between cases and 
their controls and lead to attenuation of dose–response. Rela-
tively low plutonium doses and relatively high uranium doses 
at BNFL compared with AWE would explain why such attenu-
ation would only affect the uranium excess OR/Gy. Also, the 
plutonium and uranium materials to which each cohort was 
predominantly exposed depended upon the facilities that the 
cohort covered. For example, exposures in the BNFL cohort 
were predominantly to soluble plutonium materials, whereas 
AWE workers were mainly exposed to insoluble plutonium 
materials. While the effect that different material types have 
on lung dose was taken into account in the dose assessment 
process, it is possible that some systematic bias in dose due to 
material type remained that would manifest itself on a cohort 
basis.6,25 Information on nonradiological carcinogenic coex-
posures such as organic solvents and cutting fluids, metals 
such as beryllium and lithium, and asbestos, was sparse and 
hence could not be included in risk models.
Differences in excess OR/Gy estimated for lung regions 
reflect heterogeneity of dose across the lung: risk estimates 
are highest for regions receiving lower doses and vice versa. 
It is unclear which region, if any, is the most appropriate for 
assessing risk as our analysis considered mortality and lacked 
information regarding tumor location, type, or histology. Rel-
atively low deviances of models of excess OR/Gy for total 
alpha dose to the AI region suggest that dose estimation to 
that region may provide better predictions of lung cancer risk. 
However, given uncertainties in doses, this finding cannot 
necessarily be considered to provide etiologically meaningful 
information on risk.
A few other cohorts exist in which substantial numbers 
of workers have been exposed to uranium, plutonium, and 
other alpha-emitters, in the former USSR and North America. 
Although studies of uranium and plutonium workers in the 
United States have been conducted, apart from one study of 
uranium workers,37 individual dose reconstruction of the type 
performed here has not been conducted. Applying the pres-
ent methodology to other cohorts would potentially provide 
more precise, comprehensive dose estimates on which to base 
multinational risk analyses. Results could then be compared 
with those derived from the different exposure situation of the 
MWC, which currently provides the most information on risk 
associated with internal exposures to plutonium.
CONCLUSIONS
This study is the first in which individual estimates of 
dose from multiple alpha-emitters have been used to estimate 
the risk of lung cancer mortality in large European cohorts of 
nuclear industry workers. Most subjects in the current study 
had low lung doses from uranium and/or plutonium. We found 
an increased risk of lung cancer associated with doses from 
these alpha-emitters, and although the risk appears greater 
for plutonium than for uranium, CIs are wide and overlap-
ping. Our estimates of the excess OR per Sv for alpha dose 
are higher than—but compatible with—those reported in the 
FUMC, the MWC, and atomic bomb survivors. The results 
lend further support to existing accepted risk estimates associ-
ated with internal alpha-emitters and the radiation protection 
systems based on them, although uncertainties remain and 
these findings cannot be considered definitive.
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